CERT · Insider Trading
Certara, Inc. Common Stock
Every open-market purchase and sale reported by CERT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Faiz Mohammed | Interim CFO | A | +63,532 deriv. | — |
| 2026-06-02 | Daniel Corcoran | SVP and General Counsel | MIXED | +10,727 | −$70.44K |
| 2026-06-02 | Rona Anhalt | Chief Human Resources Officer | MIXED | +4,906 | −$13.04K |
| 2026-05-15 | Matthew M Walsh | Director | M | +15,757 | — |
| 2026-05-15 | Rosemary A Crane | Director | M | +15,757 | — |
| 2026-05-15 | Nancy Killefer | Director | M | +15,757 | — |
| 2026-05-15 | James E Cashman III | Director | M | +15,757 | — |
| 2026-05-15 | Arjun Bedi | Director | M | +5,547 | — |
| 2026-05-15 | Eran Broshy | Director | M | +15,757 | — |
| 2026-05-15 | John V W Reynders | Chief Financial Officer | M | +15,757 | — |
| 2026-05-15 | Cynthia Collins | Director | M | +15,757 | — |
| 2026-05-13 | John E Gallagher | Chief Financial Officer | MIXED | +324,073 deriv. | — |
| 2026-05-13 | Daniel Corcoran | SVP and General Counsel | MIXED | +185,185 deriv. | — |
| 2026-05-13 | Jon Matthew Resnick | Chief Executive Officer | MIXED | +35,389 | −$153.82K |
| 2026-05-13 | Rona Anhalt | Chief Human Resources Officer | MIXED | +154,320 deriv. | — |
| 2026-05-13 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | +185,185 deriv. | — |
| 2026-05-13 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | +462,961 deriv. | — |
| 2026-04-03 | Rona Anhalt | Chief Human Resources Officer | MIXED | +6,702 | −$17.45K |
| 2026-04-03 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | +25,266 | −$127.74K |
| 2026-04-03 | John E Gallagher | Chief Financial Officer | MIXED | +48,843 | −$118.45K |
| 2026-04-03 | Daniel Corcoran | SVP and General Counsel | MIXED | +5,098 | −$32.78K |
| 2026-04-03 | Adrian McKemey | President, Drug Dev. Solutions | MIXED | +8,207 | −$15.06K |
| 2026-04-03 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | +36,066 | −$66.18K |
| 2026-03-02 | Arjun Bedi | Director | A | +5,547 deriv. | — |
| 2025-11-12 | William F Feehery | CHIEF EXECUTIVE OFFICER | Buy | +24,096 | +$200.00K |
| 2025-09-11 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | Sell | −51,224 | −$559.37K |
| 2025-06-02 | Daniel Corcoran | SVP and General Counsel | MIXED | +16,221 | −$75.32K |
| 2025-06-02 | Rona Anhalt | Chief Human Resources Officer | MIXED | +5,181 | −$22.40K |
| 2025-05-22 | William F Feehery | CHIEF EXECUTIVE OFFICER | A | +467,860 deriv. | — |
| 2025-05-22 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | A | +113,914 deriv. | — |
| 2025-05-22 | John E Gallagher | Chief Financial Officer | A | +170,870 deriv. | — |
| 2025-05-22 | Adrian McKemey | President, Drug Dev. Solutions | A | +81,367 deriv. | — |
| 2025-05-22 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | A | +113,914 deriv. | — |
| 2025-05-22 | Daniel Corcoran | SVP and General Counsel | A | +81,367 deriv. | — |
| 2025-05-22 | Rona Anhalt | Chief Human Resources Officer | A | +73,230 deriv. | — |
| 2025-05-22 | Eran Broshy | Director | M | +11,928 | — |
| 2025-05-22 | James E Cashman III | Director | M | +11,928 | — |
| 2025-05-22 | Cynthia Collins | Director | M | +11,928 | — |
| 2025-05-22 | Rosemary A Crane | Director | M | +11,928 | — |
| 2025-05-22 | Nancy Killefer | Director | M | +11,928 | — |
| 2025-05-22 | John V W Reynders | Director | M | +10,709 | — |
| 2025-05-22 | Matthew M Walsh | Director | M | +11,928 | — |
| 2025-04-03 | William F Feehery | CHIEF EXECUTIVE OFFICER | MIXED | +87,519 | −$532.96K |
| 2025-04-03 | John E Gallagher | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | +28,310 | −$140.34K |
| 2025-04-03 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | MIXED | +25,499 | −$81.27K |
| 2025-04-03 | Robert Aspbury | PRESIDENT, PREDICTIVE TECH | MIXED | +17,862 | −$156.88K |
| 2024-10-18 | John V W Reynders | Director | A | +10,709 deriv. | — |
| 2024-10-08 | Patrick F Smith | PRESIDENT, DRUG DEV SOLUTIONS | Sell | −5,409 | −$59.66K |
| 2024-10-07 | Patrick F Smith | PRESIDENT, DRUG DEV SOLUTIONS | MIXED | +5,409 | −$19.14K |
| 2024-09-10 | Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | Sell | −51,224 | −$578.32K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William F Feehery | CHIEF EXECUTIVE OFFICER | 2,360,769 | $29.44M |
| James E Cashman III | Director | 484,197 | $6.04M |
| Robert Aspbury | PRESIDENT, PREDICTIVE TECH | 324,393 | $4.05M |
| Matthew M Walsh | Director | 213,316 | $2.66M |
| Leif E Pedersen | PRESIDENT, CHIEF COMMERCAL OFF | 113,744 | $1.42M |
| John E Gallagher | Chief Financial Officer | 74,732 | $931.98K |
| Jon Matthew Resnick | Chief Executive Officer | 59,766 | $745.34K |
| Cynthia Collins | Director | 51,846 | $646.57K |
| Nancy Killefer | Director | 51,846 | $646.57K |
| Eran Broshy | Director | 50,708 | $632.38K |
| Rosemary A Crane | Director | 45,672 | $569.58K |
| John V W Reynders | Chief Financial Officer | 26,466 | $330.06K |
| Daniel Corcoran | SVP and General Counsel | 25,050 | $312.40K |
| Rona Anhalt | Chief Human Resources Officer | 16,789 | $209.38K |
| Adrian McKemey | President, Drug Dev. Solutions | 8,207 | $102.35K |
| Arjun Bedi | Director | 5,547 | $69.18K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CERT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.